To what extent do Mendelian Randomization Studies provide causal evidence for a particular claim if you're on a GLP-1 like semaglutide or tirzepatide

What Are Mendelian Randomization Studies?

As the founder of CFP Weight Loss and author of The Metabolic Reset Protocol, I've spent years helping adults in their late 40s and 50s navigate weight loss despite hormonal changes, joint pain, and failed diets. One powerful tool in understanding medications like semaglutide and tirzepatide is Mendelian Randomization (MR). MR uses genetic variants as natural "instruments" to infer causality, mimicking randomized controlled trials without the ethical or practical issues of assigning people to lifelong drug exposure.

Unlike observational studies that show correlations—such as lower body weight with GLP-1 use—MR helps establish whether genetic predispositions to higher GLP-1 receptor activity actually cause improvements in weight, blood sugar, or cardiovascular outcomes. For middle-income Americans managing diabetes and blood pressure, this distinction matters because insurance often denies coverage for these drugs without clear causal proof.

Causal Evidence for Weight Loss and Metabolic Benefits

MR studies provide moderate-to-strong causal evidence that lifelong higher GLP-1 signaling reduces body mass index by 0.5–1.2 kg/m² per genetically predicted standard deviation increase. In The Metabolic Reset Protocol, I highlight how this aligns with clinical data: semaglutide users lose 15% body weight on average at 2.4 mg weekly, while tirzepatide achieves 20–22% at 15 mg. MR analyses from UK Biobank data (over 400,000 participants) confirm these effects are causal, not just from appetite suppression but via direct impacts on hypothalamic signaling and adipose tissue.

For those overwhelmed by conflicting nutrition advice, MR also supports causal reductions in HbA1c by 0.2–0.4% and systolic blood pressure by 1–3 mmHg. This is crucial if joint pain makes exercise feel impossible—MR shows these metabolic shifts occur independently of physical activity levels.

Cardiovascular and Long-Term Outcomes

Recent MR research strengthens causal claims for heart protection. Variants proxying GLP-1 receptor agonists link to 10–15% lower risk of major adverse cardiovascular events, mirroring SELECT trial results with semaglutide. However, evidence is weaker for cancer risk reduction or Alzheimer's prevention; most MR studies show only suggestive, not definitive, causality due to pleiotropy—where genes affect multiple traits.

Limitations exist: MR assumes no horizontal pleiotropy and lifelong exposure, unlike the shorter-term use of semaglutide or tirzepatide. For beginners embarrassed about obesity, this means MR offers directional confidence but not perfect prediction of individual results. Combine it with my protocol's simple 3-phase meal framework—no complex plans needed.

Practical Takeaways for Real-World Use

MR studies elevate GLP-1 claims from "associated with" to "likely causes" for weight loss, glycemic control, and CV risk reduction, giving you evidence-based trust after past diet failures. Start low (0.25 mg semaglutide or 2.5 mg tirzepatide) to minimize side effects while tracking your own biomarkers. In my experience with hundreds of clients aged 45-54, pairing these medications with protein-focused, time-efficient habits from The Metabolic Reset Protocol maximizes sustainable results despite hormonal shifts.

Always consult your physician, as MR is population-level evidence, not personalized advice. This genetic lens helps cut through hype and focus on what truly moves the needle for lasting health.